Tchort
Bluelight Crew
- Joined
- Mar 25, 2008
- Messages
- 2,392
Wall Street Journal
07/29/2009
http://online.wsj.com/article/BT-CO-20090729-703121.html
07/29/2009
LONDON (Dow Jones)--Reckitt Benckiser PLC (RB.LN) has no plans to launch its own generic Suboxone product when its exclusive rights to the heroin-dependance treatment expire in October, the group's chief executive said Wednesday.
The household cleaning and personal care products maker has exclusivity for Suboxone in the U.S. until the end of September and in Europe until 2016.
Analysts have speculated that Reckitt could be planning to launch its own generic product in the U.S. to offset the impact of the loss.
"I normally wouldn't comment on this but no we're not," said CEO Bart Becht on a conference call with reporters.
He said the company was looking for other ways to offset the loss of exclusivity in the U.S. Up to 80% of the revenues and profits of the company's pharmaceuticals division might be lost to generic competition in 2010, with the possibility of further erosion thereafter, he said.
He added that the pharmaceutical business was a relatively small part of the business.
Suboxone posted net revenue of GBP219 million in the six months to June 30 and adjusted operating profit of GBP132 million.
Suboxone is a prescription drug used to treat heroin dependence.
-By Michael Carolan, Dow Jones Newswires; 44-20-7842-9278; [email protected]
http://online.wsj.com/article/BT-CO-20090729-703121.html